Evidence map›Paper›PMID 33224219›Full record

ArticleIranian journal of pharmaceutical research : IJPR2020

Two Novel Compounds with Tri-aryl Structures as Effective Anti-Breast Cancer Candidates

Ahoo Afsharinasab, Fariborz Moayer, Mohsen Amini, Samira Choopani, Raheleh Tahmasvand, Soudeh Dehghani, Seyede Zahra Mousavi, Mona Salimi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ahoo AfsharinasabDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran (IAUPS).
Fariborz MoayerDepartment of Pathobiology, College of Veterinary Medicine, Karaj Branch, Islamic Azad University, Alborz, Iran.
Mohsen AminiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Samira ChoopaniDepartment of Physiology and pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Raheleh TahmasvandDepartment of Physiology and pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Soudeh DehghaniDepartment of Physiology and pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Seyede Zahra MousaviDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran (IAUPS).
Mona SalimiDepartment of Physiology and pharmacology, Pasteur Institute of Iran, Tehran, Iran.
Pasteur Institute of Iran · IRIslamic Azad University, Karaj · IRIslamic Azad University Pharmaceutical Sciences Branch · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prognosis of metastatic breast cancer is very poor which urges the necessity to develop novel potential drug candidates. We assessed two compounds with tri-aryl structures (

Indexed as

4T1cellBALB/cBreast cancerHistopathologyTri-aryl structure

Identifiers

PMID33224219
PMCPMC7667539
OpenAlexW3087151132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.